OBP 702
Alternative Names: OBP-702; Pfifteloxin - Oncolys BiopharmaLatest Information Update: 22 Jun 2024
At a glance
- Originator Oncolys BioPharma
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 02 Mar 2023 Preclinical trials in Solid tumours in Japan (Parenteral), before March 2023 (Oncolys Biopharma pipeline, March 2023)